C3TD879 |
C3TD879 : Type I inhibitor of CIT
Probe Summary
| Targets | Biochemical/Biophysical Potency | Cellular Potency |
|---|---|---|
| CIT |
|
|
up to 1 uM
Selectivity
In Vitro Selectivity Assessment
Potency Assay Off-Target:
C3TD879 for profiling in the Eurofins KinaseProfiler assay against 373 human kinases and found it to ...
In Cell Selectivity Assessment
Potency Assay Off-Target:
C3TD879 was profiled in the NCI60 panel to look for evidence of antiproliferative activity across ma ...
Potency Cellular
In Vitro
CIT
Mode of Action: Type I
Structure-Activity-Relationship data available? Yes
DOI Reference: 10.1021/acs.jmedchem.3c01807
In Vivo Validations
Rat
Dose: 1 mg/Kg
Route of delivery:
Intravenous
Plasma half life:
4.3 h
Systemic clearance:
4.4 mL/min/kg
Cmax:
5800 nM
Area Under the Curve::
10200 nM·h
Volume of Distribution at Steady-State:
0.91 L/Kg
DOI Reference: 10.1021/acs.jmedchem.3c01807
Dose: 10 mg/Kg
Route of delivery:
Oral
Plasma half life:
4.0 h
Cmax:
12300 nM
Area Under the Curve::
7300 nM·h
Bioavailability:
72%
DOI Reference: 10.1021/acs.jmedchem.3c01807
Mouse
Dose: 30 mg/Kg
Route of delivery:
Oral
Cmax:
12900 nM (plasma), 1020 nM (brain)
Area Under the Curve::
90500 nM·h (plasma), 7710 nM·h (brain)
DOI Reference: 10.1021/acs.jmedchem.3c01807
Negative Control Compounds
C3TD879-N
Notes: C3TD879-N (cpd 59) was not able to induce thermal stabilization in biophysical assay, and did not show any binding in cellular NanoBRET experiments.
PubChem ID:
Chemical Information
| Molecular Formula | C22H28N4O |
| SMILEs | Cc1cc2c(-c3ccc(NC(=O)[C@H](N)CC(C)(C)C)cc3C)ccnc2[nH]1 |
| InChI | InChI=1S/C22H28N4O/c1-13-10-15(26-21(27)19(23)12-22(3,4)5)6-7-16(13)17-8-9-24-20-18(17)11-14(2)25-20/h6-11,19H,12,23H2,1-5H3,(H,24,25)(H,26,27)/t19-/m1/s1 |
| Molecular weight | 364.23 Da |
| AlogP | 4.548740000000003 |
| HBond acceptors | 5 |
| HBond donors | 4 |
| Atoms | 55 |
References
Publications
Vendors
Note: This is not an exhaustive list and does not indicate endorsement by the Portal.
